NEW YORK (GenomeWeb) – Medikonia said today it has inked a distribution agreement to make Amoy Diagnostics' range of molecular diagnostic tests available in Hong Kong and Macau.

Additional terms of the agreement were not disclosed.

Pau Huang, AmoyDx's international sales and marketing director, said in a statement that the firm's molecular diagnostic tests, which are powered by its proprietary PCR-based ADx Amplification Refractory Mutation System (ADx-ARMS) and Super-ARMS technologies, help patients receive the correct cancer drugs.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.